VCU Massey Cancer Center becomes the first cancer care provider in Virginia to perform next-generation genome sequencing for precision cancer treatment
VCU Massey Cancer Center has taken precision medicine in Virginia to the next level with the introduction of advanced genomic sequencing for the treatment of cancer. Patients now have in-house access to Oncogenomics DX1, a single test that can sequence their cancer’s DNA and match them with existing or experimental therapies that target the specific molecule or gene driving their disease.
Knowledge of genetic cancer risks often dies with patients
If you were dying from cancer, would you consider genetic testing? A recent study conducted by researchers from Virginia Commonwealth University Massey Cancer Center showed that most terminally ill cancer patients who were eligible for genetic testing never received it despite the fact that it could potentially save a relative's life.
New approaches refine molecular imaging for detecting cancer metastasis
In the new study, published online in the December issue of the journal Nature Medicine, VCU researchers, together with researchers from the Johns Hopkins Medical Institutions, have shown how the genetic element, known as progression elevated gene-3 promoter, or PEG-Prom, can be used to image metastases in multiple animal models of human melanoma and human breast metastasis. The system can be used to measure gene expression, protein interaction or track gene-tagged cells in vivo. This approach offers significant advantages in sensitivity and accuracy over currently used imaging strategies.
Novel therapy for metastatic kidney cancer developed at VCU Massey and VCU Institute for Molecular Medicine
Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus. Renal cell carcinoma is the most common form of kidney cancer in adults and currently there is no effective treatment for the disease once it has spread outside of the kidney.oma and brain, prostate, pancreatic, breast and colon cancers.
VCU Massey Cancer Center first to combine targeted agents to kill multiple myeloma cells
Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal Blood, are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.